It depends on whether or not the patients treated were MRD+. These patients were from cohorts 4 and 5 of the study which is using the new manufacturing process testing different doses. The results theoretically should help determine which dose level they will use for the trial. These cohorts do not specifically define MRD positivity so there is no guarantee that the patients were MRD+.
It isn't until they finally get their act together and start enrolling their actual trial that we will see the split off in the active group of frank relapse patients and MRD+ patients.
Enrollment was supposed to resume last year so hopefully we get some enrollment numbers with their next news dump that should be next week.
News 
Market Data 
Discover 
AI
